Page 8 - Generation Bio News Today

In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline. Masimo CEO waives right to $600 million payout in fight with activist investor Masimo Corp Chief Executive Joe Kiani has waived his rights for roughly $600 million in special payment if the U.S. medical device maker appoints a lead independent ...

Shares of Generation Bio Co. (GBIO) are rising more than 25% Thursday morning after the company announced collaboration with Moderna, Inc. (MRNA) to develop non-viral genetic medicines.

(Reuters) - Moderna Inc said on Thursday it had entered into a licensing deal and would make a $36 million equity investment in Generation Bio Co to d...

Moderna and Generation Bio plan to develop non-viral genetic medicines for immune system and liver disorders under an up-to-$1.9 billion collaboration.

BioPharma

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people...

/PRNewswire/ -- Technavio categorizes the global gene therapy market size as estimated to increase by USD 4,613.9 million between 2022 and 2027. The markets...

— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of $279.1M provides expected runway into...

EQS-News: BB Biotech AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: Divergent biotech equity markets mirror value over grow...

Visiongain has published a new report entitled Gene Therapy R&D 2022-2032. It includes profiles of Gene Therapy R&D and Forecasts Market Segment by...